The day after completing its latest billion-dollar deal, Boston Scientific dispatched food trucks to hand out fried chicken ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

On Friday, Boston Scientific Corporation (BSX) stock saw a modest uptick, ending the day at $88.25 which represents a slight increase of $1.37 or 1.58% from the prior close of $86.88. The stock opened ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Boston Scientific’s BSX net income was $469 million, or 32 cents a share, down from $505 million, or 34 cents a share, in the ...

Boston Scientific Corp. resumed enrollment in the AVANT GUARD trial of the Farapulse pulse field ablation (PFA) system after a pause reported in October “to assess a few unanticipated observations.” ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...